Sun Pharmaceutical Industries Ltd (SUNPHARMA)
Healthcare · Pharmaceuticals · NSE · Updated 1 October 2026
₹1,860↑ 16.62% (1Y)
🎯 Key Takeaways
- Revenue grew 4.7% QoQ to ₹15,300 in Q1FY27.
- Market Cap
- ₹4.46 L Cr
- P/E Ratio
- 36.9
- P/B Ratio
- 5.34
- ROE
- 14.5%
- ROCE
- 18.7%
- Debt/Equity
- 0.05
- Div Yield
- 0.86%
- Promoter
- 54.5%
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 13,851 | 14,478 | 15,521 | 14,612 | 15,300 |
| Operating Profit | 3,601 | 3,798 | 4,216 | 3,179 | 3,679 |
| OPM % | 26.0% | 26.2% | 27.2% | 21.8% | 24.1% |
| Net Profit | 2,303 | 3,137 | 3,401 | 2,724 | 2,911 |
| EPS | ₹9.50 | ₹13.00 | ₹14.00 | ₹11.30 | ₹12.10 |
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 240 | 240 | 240 | 240 |
| Reserves | 71,978 | 68,875 | 83,330 | 77,580 |
| Borrowings | 2,362 | 2,572 | 4,082 | 5,215 |
| Total Liabilities | 92,101 | 88,116 | 1.09 L Cr | 1.04 L Cr |
| Fixed Assets | 10,036 | 10,098 | 34,493 | 10,407 |
| Investments | 18,354 | 17,744 | 24,723 | 19,543 |
| Total Assets | 92,101 | 88,116 | 1.09 L Cr | 1.04 L Cr |
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +12,419 |
| Investing | -11,344 |
| Financing | -2,513 |
| Net Cash Flow | -1,437 |
👥 Shareholding Pattern
| Category | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 54.5% | 54.5% | 54.5% | 54.5% | 54.5% | 54.5% | 54.5% | 54.5% |
| FII | 18.0% | 18.1% | 18.0% | 17.3% | 16.6% | 16.1% | 15.9% | 14.5% |
| DII | 18.6% | 18.6% | 18.7% | 19.5% | 20.2% | 20.8% | 21.1% | 22.2% |
| Public | 5.4% | 5.5% | 5.4% | 5.3% | 5.5% | 5.4% | 5.3% | 5.5% |
| # Shareholders | 6,57,317 | 6,89,623 | 7,04,983 | 7,23,770 | 7,43,877 | 7,10,900 | 6,90,957 | 7,10,246 |
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.46 L Cr | 36.9 | 18.7% | — | 0.05 |
| DIVISLAB | 2.52 L Cr | 86.0 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.87 L Cr | 78.4 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.19 L Cr | 26.6 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.1 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.07 L Cr | 98.0 | 20.8% | — | 0.45 |
| MANKIND | 1.05 L Cr | 51.4 | 13.9% | — | 0.38 |
| DRREDDY | 1.04 L Cr | 32.3 | 10.1% | — | 0.17 |
| AUROPHARMA | 97,987 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,190 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
📋 Recent Filings
- 🟡 corporate governance2026-09-29Sun Pharmaceutical Industries Ltd submitted its ESG Overview for FY 2025-26, detailing governance changes including board composition updates, committ…
- 🟡 voting results2026-09-28Sun Pharmaceutical Industries announced the completion of its postal ballot dated 25 August 2026, confirming that all resolutions were approved by the…
- 🔴 Announcement2026-09-28Sun Pharma announced a global licensing deal with LIB Therapeutics for lerodalcibep, a PCSK9 inhibitor approved in the EU, granting Sun exclusive righ…
- 🟡 Shareholding Pattern2026-09-26Sun Pharmaceutical Industries announced that shareholders approved reclassifying the promoter group category to public on 26 September 2026, effective…
- Announcement2026-09-25Sun Pharmaceutical announces that its trading window will close on 1 October 2026 and remain shut until 48 hours after the unaudited quarterly results…
- 🔴 Announcement2026-09-22Sun Pharmaceutical Industries Limited presented its investor outlook for FY26, highlighting a diversified revenue base of Rs 582 Bn with 29% from US f…
- 🔴 Announcement2026-09-11Sun Pharmaceutical announced a confidential settlement with a plaintiff in the In re Generic Pharmaceuticals Pricing Antitrust Litigation, releasing a…
- 🔴 Announcement2026-09-09Sun Pharmaceutical announced the incorporation of a wholly owned subsidiary, Sun Pharma Global Treasury Centre IFSC Limited, in GIFT City, Gujarat, to…
- 🔴 Announcement2026-09-08Sun Pharmaceutical Industries Limited announced international credit ratings from Moody's and S&P Global following its proposed $11.75 billion acquisi…
- 🔴 Announcement2026-09-03Sun Pharmaceutical announced its schedule of upcoming analyst and institutional investor meetings in September 2026, including events with UBS, Jeffer…
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-10-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when SUNPHARMA files new disclosures
Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track SUNPHARMA — FreeFree account · 2 AI queries/day